Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.

STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer

Open access
Delgado-Ramirez, Yael, Baltazar-Perez, Itzel, Martinez, Yamileth, Callejas, Blanca E., Medina-Andrade, Itzel, Olguín, Jonadab E., Delgado-Buenrostro, Norma L., Chirino, Yolanda I., Terrazas, Luis I., Leon-Cabrera, Sonia · 2021 · International Journal of Molecular Sciences

Abstract

Signal transducer and activator of transcription 1 (STAT1) acts as a tumor suppressor molecule in colitis-associated colorectal cancer (CAC), particularly during the very early stages, modulating immune responses and controlling mechanisms such as apoptosis and cell proliferation. Previously, using an experimental model of CAC, we reported increased intestinal cell proliferation and faster tumor development, which were consistent with more signs of disease and damage, and reduced survival in STAT1-/- mice, compared with WT counterparts. However, the mechanisms through which STAT1 might prevent colorectal cancer progression preceded by chronic inflammation are still unclear. Here, we demonstrate that increased tumorigenicity related to STAT1 deficiency could be suppressed by IL-17 neutralization. The blockade of IL-17 in STAT1-/- mice reduced the accumulation of CD11b+Ly6ClowLy6G+ cells resembling granulocytic myeloid-derived suppressor cells (MDSCs) in both spleen and circulation. Additionally, IL-17 blockade reduced the recruitment of neutrophils into intestinal tissue, the expression and production of inflammatory cytokines, and the expression of intestinal STAT3. In addition, the anti-IL-17 treatment also reduced the expression of Arginase-1 and inducible nitric oxide synthase (iNOS) in the colon, both associated with the main suppressive activity of MDSCs. Thus, a lack of STAT1 signaling induces a significant change in the colonic microenvironment that supports inflammation and tumor formation. Anti-IL-17 treatment throughout the initial stages of CAC related to STAT1 deficiency abrogates the tumor formation possibly caused by myeloid cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22147695

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Macrophage populations are reduced in STAT1-/- AOM/DSS-treated mice: (A) schematic time schedule of azoxymethane (AOM) and dextran sodium sulfate (DSS) administration. After the initial AOM injection (12.5 mg/kg), DSS was given in drinking water for 7 days followed by 14 days of regular drinking water. Mice were sacrificed on days 20, 40 (early tumor development), and 77 (late tumor development) post-AOM injection; (B) representative microscopic images showing immunohistochemical staining of F4/80 macrophages in colon tumor sections from WT and STAT1-/- mice treated with AOM/DSS at different times of tumor progression Scale bars: 50 µm; (C) percentage of cells stained positive for F4/80; (D) representative dot plots showing CD11b+F4/80+ cell populations in spleens of WT and STAT1-/- mice treated with AOM/DSS at the indicated time intervals; (E) percentages of CD11b+ F4/80+ cells in the splenocytes of WT and STAT1-/- mice treated with AOM/DSS at different times of tumor progression; (F) immunohistochemical staining and (G) percentage of Ly6G+ cells in colon tissues in day 20. The quantification of Ly6G+ cells was performed using ImageJ software v.1.48 by counting cells in 10 high-powered fields from at least three slides per animal. Scale bars: 50 µm.The red arrowheads indicate Ly6G localization. Data shown are the mean ± SE of four or five individual mice per group per day of analysis and are representative of three individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 1 Macrophage populations are reduced in STAT1-/- AOM/DSS-treated mice: (A) schematic time schedule of azoxymethane (AOM) and dextran sodium sulfate (DSS) administration. After the initial AOM injection (12.5 mg/kg), DSS was given in drinking water for 7 days followed by 14 days of regular drinking water. Mice were sacrificed on days 20, 40 (early tumor development), and 77 (late tumor development) post-AOM injection; (B) representative microscopic images showing immunohistochemical staining of F4/80 macrophages in colon tumor sections from WT and STAT1-/- mice treated with AOM/DSS at different times of tumor progression Scale bars: 50 µm; (C) percentage of cells stained positive for F4/80; (D) representative dot plots showing CD11b+F4/80+ cell populations in spleens of WT and STAT1-/- mice treated with AOM/DSS at the indicated time intervals; (E) percentages of CD11b+ F4/80+ cells in the splenocytes of WT and STAT1-/- mice treated with AOM/DSS at different times of tumor progression; (F) immunohistochemical staining and (G) percentage of Ly6G+ cells in colon tissues in day 20. The quantification of Ly6G+ cells was performed using ImageJ software v.1.48 by counting cells in 10 high-powered fields from at least three slides per animal. Scale bars: 50 µm.The red arrowheads indicate Ly6G localization. Data shown are the mean ± SE of four or five individual mice per group per day of analysis and are representative of three individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY · PubMed Central
Figure 2 STAT1 deficiency increases the accumulation of CD11b+Ly6ClowLy6G+ granulocytic cells: (A) representative flow cytometry plots in the spleen are shown with Ly6C and Ly6G markers of gated living CD11b+ population cells on day 20. The bar graph illustrates the percentages of cell populations in the spleen (B) and blood (C) at the indicated time intervals (day 20 and day 77), gated as in Figure 2A. Data shown are the mean ± SEM of four or five individual mice per group per day of analysis and are representative of two individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 2 STAT1 deficiency increases the accumulation of CD11b+Ly6ClowLy6G+ granulocytic cells: (A) representative flow cytometry plots in the spleen are shown with Ly6C and Ly6G markers of gated living CD11b+ population cells on day 20. The bar graph illustrates the percentages of cell populations in the spleen (B) and blood (C) at the indicated time intervals (day 20 and day 77), gated as in Figure 2A. Data shown are the mean ± SEM of four or five individual mice per group per day of analysis and are representative of two individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY · PubMed Central
Figure 3 Therapeutic efficacy of IL-17 neutralization in STAT1-/- mice during CAC: (A) WT or STAT1−/− mice were injected with isotype control or anti-IL-17 neutralizing antibody from day 7 to 19 every other day (black arrows) after AOM/DSS administration. On day 77, the animals were euthanized to analyze tumor development; (B) weight changes in WT and STAT1-/- mice with isotype and anti-IL17-treated mice. The mean weight of mice on day 0 of treatment was taken as 100% and was compared with the weekly weight until the end of the experiment; (C) the disease activity index (DAI) score was assessed on the indicated days for each animal and averaged per day for each group; (D) colon length, (E) macroscopic images of the colon (asterisks are pointing to the tumors), (F) number and (G) size of tumors 77 days after AOM injection; (H) colon sections stained with H&E as well as with Alcian blue to visualize goblet cells. Scale bars: 50 µm. Data shown are the mean ± SEM of at least four or five mice per group and are representative of two individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3 Therapeutic efficacy of IL-17 neutralization in STAT1-/- mice during CAC: (A) WT or STAT1−/− mice were injected with isotype control or anti-IL-17 neutralizing antibody from day 7 to 19 every other day (black arrows) after AOM/DSS administration. On day 77, the animals were euthanized to analyze tumor development; (B) weight changes in WT and STAT1-/- mice with isotype and anti-IL17-treated mice. The mean weight of mice on day 0 of treatment was taken as 100% and was compared with the weekly weight until the end of the experiment; (C) the disease activity index (DAI) score was assessed on the indicated days for each animal and averaged per day for each group; (D) colon length, (E) macroscopic images of the colon (asterisks are pointing to the tumors), (F) number and (G) size of tumors 77 days after AOM injection; (H) colon sections stained with H&E as well as with Alcian blue to visualize goblet cells. Scale bars: 50 µm. Data shown are the mean ± SEM of at least four or five mice per group and are representative of two individual experiments with similar results per day of the analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY · PubMed Central
Figure 4 Anti-IL-17 treatment affects the recruitment of neutrophils and CD11b+Ly6ClowLy6G+ cell populations in STAT1-/- mice. Mice were treated as in Figure 3A. Circulating cells were obtained from tumor-bearing WT or STAT1-/- mice treated with anti-IL-17(αIL-17) or isotype (iso) antibodies. (A) representative flow cytometry plots are shown with Ly6C and Ly6G markers of gated living CD11b+ population cells in blood; (B) the bar graph illustrates the frequencies of CD11b+Ly6ChiLy6G-and CD11b+Ly6ClowLy6G+ cell populations in blood at the indicated time intervals (day 20 and day 77), gated as in Figure 4A; (C) representative immunohistochemical staining of Ly6G in colon tissue at day 77. The arrowheads indicate Ly6G localization. Scale bars: 50 µm; (D) confocal representatives merged images of the immunofluorescence staining of the distal/affected colon tissue at day 77 using an anti-iNOS antibody (green) or anti-Arginase-1 antibody (green) and DAPI (blue) counterstaining. The images were captured in a confocal microscope at 63X. Scale bars = 20 μm. Relative fluorescence for iNOS (E) and Arginase-1 (F); (G) representative immunohistochemical staining of phosphorylated STAT3 in colon tissue at day 77. The arrowheads indicate pSTAT3 localization. Scale bars: 100 µm; (H) percentage of cells stained positive for pSTAT3. The quantification of Ly6G+ cells and pSTAT3+ cells was performed using ImageJ software v.1.48 by counting cells in 10 high-powered fields from at least three slides per animal. Data shown are the mean ± SEM of at least four or five mice per group and are representative of two individual experiments with similar results. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 4 Anti-IL-17 treatment affects the recruitment of neutrophils and CD11b+Ly6ClowLy6G+ cell populations in STAT1-/- mice. Mice were treated as in Figure 3A. Circulating cells were obtained from tumor-bearing WT or STAT1-/- mice treated with anti-IL-17(αIL-17) or isotype (iso) antibodies. (A) representative flow cytometry plots are shown with Ly6C and Ly6G markers of gated living CD11b+ population cells in blood; (B) the bar graph illustrates the frequencies of CD11b+Ly6ChiLy6G-and CD11b+Ly6ClowLy6G+ cell populations in blood at the indicated time intervals (day 20 and day 77), gated as in Figure 4A; (C) representative immunohistochemical staining of Ly6G in colon tissue at day 77. The arrowheads indicate Ly6G localization. Scale bars: 50 µm; (D) confocal representatives merged images of the immunofluorescence staining of the distal/affected colon tissue at day 77 using an anti-iNOS antibody (green) or anti-Arginase-1 antibody (green) and DAPI (blue) counterstaining. The images were captured in a confocal microscope at 63X. Scale bars = 20 μm. Relative fluorescence for iNOS (E) and Arginase-1 (F); (G) representative immunohistochemical staining of phosphorylated STAT3 in colon tissue at day 77. The arrowheads indicate pSTAT3 localization. Scale bars: 100 µm; (H) percentage of cells stained positive for pSTAT3. The quantification of Ly6G+ cells and pSTAT3+ cells was performed using ImageJ software v.1.48 by counting cells in 10 high-powered fields from at least three slides per animal. Data shown are the mean ± SEM of at least four or five mice per group and are representative of two individual experiments with similar results. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY · PubMed Central
Figure 5 Treatment with anti-IL-17 antibody reduced the pro-inflammatory cytokine production in the spleens of STAT1-/- mice. Mice were treated as in Figure 3A. In total, 1 × 105 spleen cells were obtained at day 20 after AOM/DSS treatment and were stimulated with α-CD3 for 72 h to analyze the expressions of (A) IFN-γ, (B) IL-6, (C) IL-17A, (D) IL-10, and (E) TNF-α cytokines using the Mouse Th1/Th2/Th17 CBA Kit (BD®). Total spleen cells were analyzed by flow cytometry. Frequencies of total (F) CD4+ cells, (G) CD8+ cells, and (H) CD4+Foxp3+CD25+ T cells of tumor-bearing WT iso, STAT1-/- iso or WT or STAT1-/- mice treated with anti-IL-17 neutralizing antibody. Data shown are the mean ± SEM of three or four individual mice per group and are representative of two individual experiments with similar results. * p < 0.05, ** p < 0.01, ***p < 0.001.
Figure 5 Treatment with anti-IL-17 antibody reduced the pro-inflammatory cytokine production in the spleens of STAT1-/- mice. Mice were treated as in Figure 3A. In total, 1 × 105 spleen cells were obtained at day 20 after AOM/DSS treatment and were stimulated with α-CD3 for 72 h to analyze the expressions of (A) IFN-γ, (B) IL-6, (C) IL-17A, (D) IL-10, and (E) TNF-α cytokines using the Mouse Th1/Th2/Th17 CBA Kit (BD®). Total spleen cells were analyzed by flow cytometry. Frequencies of total (F) CD4+ cells, (G) CD8+ cells, and (H) CD4+Foxp3+CD25+ T cells of tumor-bearing WT iso, STAT1-/- iso or WT or STAT1-/- mice treated with anti-IL-17 neutralizing antibody. Data shown are the mean ± SEM of three or four individual mice per group and are representative of two individual experiments with similar results. * p < 0.05, ** p < 0.01, ***p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 52 references

Cited by

See all 20

Metadata

Authors
Delgado-Ramirez, Y., Baltazar-Perez, I., Martinez, Y., Callejas, B. E., Medina-Andrade, I., Olguín, J. E., Delgado-Buenrostro, N. L., Chirino, Y. I., Terrazas, L. I., & Leon-Cabrera, S.
Affiliations
  • Universidad Nacional Autónoma de México, Facultad de Estudios Superiores Iztacala (MX)
  • Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Edo. De México 54090, Mexico
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-07-19
Volume
22
Issue
14
Pages
7695
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3185720931
Cited by
19
References
52
Citations by year
2025: 6 · 2024: 6 · 2023: 3 · 2022: 4
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • CONACYT (A1S23944 and 315817)
  • Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, PAPIIT, UNAM. (IN215421 and IN226519)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
STAT1, colitis-associated colorectal cancer, IL-17, myeloid-derived suppressor cells, granulocytic MDSCs, neutrophil recruitment, tumor suppressor, STAT3, arginase-1, inducible nitric oxide synthase, chronic intestinal inflammation, tumor microenvironment, STAT1-deficient mice
MeSH terms
Myeloid-Derived Suppressor Cells, Colitis-Associated Neoplasms, Animals, Female, Granulocytes, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Disease Progression, Interleukin-17, STAT1 Transcription Factor, Mice, Antibodies, Neutralizing, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer. https://app.cochat.ai/papers/10.3390/ijms22147695
The paper
Delgado-Ramirez, Y., Baltazar-Perez, I., Martinez, Y., Callejas, B. E., Medina-Andrade, I., Olguín, J. E., Delgado-Buenrostro, N. L., Chirino, Y. I., Terrazas, L. I., & Leon-Cabrera, S. (2021). STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22147695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.